European Commission Approves Pfizer’s HYMPAVZI (marstacimab) for the Treatment of Adults and Adolescents with Severe ...
Pfizer Inc. announced that the European Commission (EC) has granted marketing authorization for HYMPAVZI (marstacimab) for the routine prophylaxis of bleeding episodes in patients 12 years of age and older weighing at least 35 kg with severe hemophilia A ( …